Shingles

Shingles (also known as herpes zoster) results from infection by the varicella zoster virus. This common virus causes chickenpox (also known as varicella), which is characterized by itchy spots on the skin that cover the whole body and usually occurs in childhood or adolescence. After the body fights the initial infection, the varicella zoster virus remains in nerve cells for the rest of a person’s life. Because the virus is controlled by immune system cells called T cells, it is generally inactive (latent) and typically causes no health problems. However, in some people, the virus becomes active again (reactivates) and causes shingles. Shingles can occur at any age, although it is rare in childhood and becomes more common after age 50.

Shingles is characterized by a severely painful, itchy, or tingling rash, most commonly on one side of the torso, although it can occur anywhere on the body. Reactivation of the virus usually occurs in a single nerve, leading to the symptoms of shingles in just the region of skin connected to that nerve. When the nerve connected to the eye and the skin surrounding it is affected, the condition is called herpes zoster ophthalmicus. This form of shingles, which accounts for about 20 percent of cases, can cause permanent vision impairment.

Some individuals with shingles feel throbbing or tingling in the affected region shortly before the rash appears. Blisters form in the rash area, break open, and scab over in a few days. Healing usually takes 2 to 4 weeks. Most people have only one episode of shingles, although it can recur in rare cases.

In 5 to 20 percent of people with shingles, severe pain continues in the affected region after healing of the rash, which is known as postherpetic neuralgia (PHN). PHN is the most common complication of shingles. It can also involve severe itchiness or an overactive pain response to things that do not usually cause pain (allodynia), such as a light touch. PHN can last weeks, months, or even years. The likelihood of developing PHN after shingles and its severity increase with age. The pain caused by shingles and PHN can disrupt day-to-day activities and reduce a person’s quality of life.

Frequency

Because everyone infected with the varicella zoster virus is at risk of developing shingles, the condition is relatively common, particularly in older adults. Shingles occurs in 20 to 30 percent of people at some point in their lives, and about half of people over age 80 have had shingles.

The risk of shingles varies by ethnic background. The condition is more common in people of non-Hispanic white ancestry than those of African American ancestry. For unknown reasons, women are more prone to develop shingles than men.
A vaccine to prevent chickenpox was introduced in the United States in 1995. Since then, the incidence of chickenpox has been reduced by 76 to 85 percent. Doctors suspect the reduction of varicella zoster virus infections will reduce the incidence of shingles as the vaccinated children grow into adulthood; however, it is too early to tell. Vaccines for adults to protect against shingles and subsequent PHN have been used since 2006 and are also expected to reduce the incidence of shingles and its complications.

**Causes**

The causes of shingles are complex. Development of the condition is influenced by a combination of factors, including age, health, and genetics.

The strongest risk factor for shingles is age. The varicella zoster virus is controlled by the immune system, particularly T cells that keep the virus from infecting other cells. As people age, growth and division (proliferation) of T cells are diminished, reducing the immune system's ability to control the virus, which can allow its reactivation. Health factors that impair T cells can also trigger reactivation of the varicella zoster virus. For example, certain drugs, such as chemotherapies used to treat blood cancers like multiple myeloma or drugs that prevent rejection of a transplanted organ, impair the immune system and can lead to virus reactivation. Infection with human immunodeficiency virus (HIV), which infects and kills T cells, can also allow the virus to become active again. In addition, some studies suggest that emotional stress or physical trauma may be involved in virus reactivation.

The role of genetics in shingles is not clear. Several studies indicate that having a family member who developed the condition increases a person's risk, suggesting a shared genetic risk factor, although other studies did not find such a link. Genes that help regulate the immune system have been found in some studies to be associated with the development of shingles or of PHN after shingles. In particular, the risk of developing PHN appears to be increased by certain variants of genes that belong to a family of genes called the human leukocyte antigen (HLA) complex. The HLA complex helps the immune system distinguish the body's own proteins from proteins made by foreign invaders such as viruses and bacteria. It is unclear if certain HLA variations also play a role in the development of shingles.

**Inheritance Pattern**

The inheritance pattern of shingles is unclear. Having a first-degree relative (such as a parent or sibling) who developed shingles appears to slightly increase the risk of developing the condition. However, shingles is relatively common in the general population, particularly among older adults, and so it would not be surprising to see more than one case in a family just by chance.
Other Names for This Condition
- herpes zoster
- zoster

Diagnosis & Management

Formal Treatment/Management Guidelines
- Canadian Medical Association: Recommendations for Zoster Immunization Programs
- Canadian Medical Association: Safety and Effectiveness of the Herpes Zoster Vaccine to Prevent Postherpetic Neuralgia: 2014 Update an Consensus Statement from the Canadian Pain Society
- Cochrane Library: Antiviral Treatment for Preventing Postherpetic Neuralgia
- Cochrane Library: Vaccines for Preventing Herpes Zoster in Older Adults

Research Studies from ClinicalTrials.gov
- ClinicalTrials.gov
  https://clinicaltrials.gov/ct2/results?cond=%22shingles%22+OR+%22Herpes +Zoster%22

Other Diagnosis and Management Resources
- Centers for Disease Control and Prevention: What Everyone Should Know About Shingles Vaccine
- MedlinePlus Drug Information: Shingles (Zoster) Vaccine
  https://medlineplus.gov/druginfo/meds/a607025.html
- MedlinePlus Encyclopedia: Postherpetic Neuralgia - Aftercare
  https://medlineplus.gov/ency/patientinstructions/000555.htm
- MedlinePlus Encyclopedia: Shingles
  https://medlineplus.gov/ency/article/000858.htm
- National Health Service (UK): Post-Herpetic Neuralgia Treatment
  https://www.nhs.uk/conditions/post-herpetic-neuralgia/treatment/
Additional Information & Resources

Health Information from MedlinePlus

• Drug Information: Shingles (Zoster) Vaccine
  https://medlineplus.gov/druginfo/meds/a607025.html

• Encyclopedia: Chickenpox
  https://medlineplus.gov/ency/article/001592.htm

• Encyclopedia: Postherpetic Neuralgia - Aftercare
  https://medlineplus.gov/ency/patientinstructions/000555.htm

• Encyclopedia: Shingles
  https://medlineplus.gov/ency/article/000858.htm

• Health Topic: Shingles
  https://medlineplus.gov/shingles.html

Genetic and Rare Diseases Information Center

• Herpes zoster oticus

Additional NIH Resources

• National Institute of Neurological Disorders and Stroke
  https://www.ninds.nih.gov/Disorders/All-Disorders/Shingles-Information-Page

Educational Resources

• American Academy of Ophthalmologists: What is Shingles?
  https://www.aao.org/eye-health/diseases/herpes-zoster-shingles

• Centers for Disease Control and Prevention: Chickenpox Vaccine Information Sheet
  https://www.cdc.gov/vaccines/hcp/vis/vis-statements/varicella.html

• Centers for Disease Control and Prevention: Shingles (Herpes Zoster)
  https://www.cdc.gov/shingles/hcp/clinical-overview.html

• KidsHealth from Nemours: Chickenpox

• KidsHealth from Nemours: Shingles

• MalaCards: herpes zoster
  https://www.malacards.org/card/herpes_zoster

• Merck Manual Consumer Version: Herpes Zoster Ophthalmicus
• Merck Manual Consumer Version: Postherpetic Neuralgia
  https://www.merckmanuals.com/home/infections/herpesvirus-infections/postherpetic-neuralgia

• Merck Manual Consumer Version: Shingles
  https://www.merckmanuals.com/home/infections/herpesvirus-infections/shingles

• National Health Service (UK): Post-Herpetic Neuralgia Overview
  https://www.nhs.uk/conditions/post-herpetic-neuralgia/

• New York State Department of Health

Patient Support and Advocacy Resources

• American Chronic Pain Association
  https://www.theacpa.org/conditions-treatments/conditions-a-z/postherpetic-neuralgia-shingles/

• National Foundation for Infectious Diseases
  http://www.nfid.org/shingles

• Shingles Support Society
  https://shinglessupport.org.uk/

Scientific Articles on PubMed

• PubMed
  https://www.ncbi.nlm.nih.gov/pubmed?term=%28%28Herpes+Zoster%5BTI%5D%29+OR+%28shingles%5BTI%5D%29%29+AND+english%5Bla%5D+AND+human%5Bmh%5D+AND+%22last+360+days%22%5Bdp%5D

Medical Genetics Database from MedGen

• Herpes zoster

Sources for This Summary

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/17204399

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/25297839
  Free article on PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4308645/


Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/27114460
Free article on PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4920021/

Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/29047317

Reprinted from Genetics Home Reference:

Reviewed: January 2018
Published: May 28, 2019

Lister Hill National Center for Biomedical Communications
U.S. National Library of Medicine
National Institutes of Health
Department of Health & Human Services